Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study

AIM: Radium‐223, a targeted alpha therapy, is approved widely for the treatment of patients with metastatic castrate‐resistant prostate cancer, based on a pivotal phase 3 study in predominantly white patients. We investigated the efficacy and safety of radium‐223 in Asian patients with castrate‐resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Tie, Zhou, Fangjian, Guo, Jianming, Shi, Hongcheng, Yao, Xudong, Guo, Hongqian, Yuan, Jian, Tian, Ye, Zhang, Xiaodong, Wang, Shuxia, Jiang, Yongguang, Zou, Qing, Zhou, Daqing, Li, Hanzhong, Li, Fang, Lee, Jae Lyun, Chen, Chung‐Hsin, Park, Se Hoon, Ng, Quan Sing, Ma, Jianhui, Zheng, Rong, Ding, Qiang, Liu, Xingdang, Li, Rui, Krissel, Heiko, Wagner, Volker J., Sun, Yinghao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292681/
https://www.ncbi.nlm.nih.gov/pubmed/33051982
http://dx.doi.org/10.1111/ajco.13479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292681/
https://www.ncbi.nlm.nih.gov/pubmed/33051982
http://dx.doi.org/10.1111/ajco.13479

Ejemplares similares